New PhI­II da­ta in hand, Pfiz­er, Astel­las hus­tle ahead in bid to ex­pand US mar­ket for Xtan­di

Pfiz­er $PFE just got some bad­ly need­ed good news for its new­ly ac­quired can­cer drug Xtan­di.

Af­ter watch­ing sales sink right af­ter it ac­quired the ther­a­py and all of Medi­va­tion for $14 bil­lion, re­searchers say the drug cleared the Phase III study for non-metasta­t­ic, cas­tra­tion re­sis­tant prostate can­cer. And at least one promi­nent an­a­lyst says that’s a big deal as Pfiz­er and its part­ners at Astel­las look to build sales for this key ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.